
Breakthrough bone cancer drug slows tumor growth, extends survival in early studies
Fox News
For those suffering from primary bone cancer, a promising new medication called CADD522 may be on the horizon. In early tests, it extended survival and reduced tumor growth.
In a recent study of mice, CADD522 significantly reduced tumor volume, increased survival and reduced cancer-induced bone disease — all without surgery. "I hope that my work and the development of this new drug does him proud and carries his legacy forever." The new drug resulted in a 50% increase in survival rates for all main types of bone cancer. Melissa Rudy is health editor and a member of the lifestyle team at Fox News Digital.
The study, which appeared in the Journal of Bone Oncology, was led by the University of East Anglia in Norwich, England, along with researchers from the University of Sheffield, Newcastle University, the Royal Orthopaedic Hospital in Birmingham, and the Norfolk & Norwich University Hospital.